2500x1875bg3.jpg
2500x1875bg3.jpg

Bio


Partnering on novel technologies is critical for success.

SCROLL DOWN

Bio


Partnering on novel technologies is critical for success.

 

WHAT IS PRECISION MEDICINE?

“It's more important to know what sort of person has a disease than what sort of disease a person has.”
–Hippocrates

 

Our Team


Stelvio Oncology has developed an epigenetic signature based platform for identifying compounds that drive differentiation of cancer stem cells into benign cell types.

Our Team


Stelvio Oncology has developed an epigenetic signature based platform for identifying compounds that drive differentiation of cancer stem cells into benign cell types.

  Attila Hajdu, MBA, MSc ,   Chief Executive Officer  ,   Founder ,  STELVIO ONCOLOGY

Attila Hajdu, MBA, MSc, Chief Executive Officer, Founder, STELVIO ONCOLOGY

  Alexey V. Terskikh ,  Ph.D.,    Co-Founder,   STELVIO ONCOLOGY Associate Professor, Development, Aging and Regeneration Program  Sanford Burnham Prebys Medical Discovery Institute

Alexey V. Terskikh, Ph.D., Co-Founder, STELVIO ONCOLOGY
Associate Professor, Development, Aging and Regeneration Program
Sanford Burnham Prebys Medical Discovery Institute

  David Andrews, PhD  Director of Biological Sciences, Professor of Biochemistry,  University of Toronto

David Andrews, PhD
Director of Biological Sciences, Professor of Biochemistry,
University of Toronto

  David Spaner, MD, PhD  Medical Oncologist/Hematologist, Sen ior Scientist,   Sunnybrook Health Sciences Centre

David Spaner, MD, PhD
Medical Oncologist/Hematologist, Senior Scientist,
Sunnybrook Health Sciences Centre

About our team

Stelvio Oncology has core competencies of scientific creativity, clinical excellence and professional management required to successfully commercialize novel drug therapies and precision medicine diagnostics.